Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

被引：0
|
作者：
Phan, A. T. [1 ]
Wolin, E. M. [2 ]
Fisher, G. A. [3 ]
Ruszniewski, P. [4 ]
Pavel, M. [5 ]
Liyanage, N. [6 ]
Mirakhur, B. [7 ]
Braun, S. [6 ]
Caplin, M. [8 ]
Vinik, A., I [9 ]
机构：
[1] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA
[2] Montefiore Einstein Ctr Canc Care, Bronx, NY USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Beaujon Hosp, Clichy, France
[5] Charite Univ Med Berlin, Berlin, Germany
[6] Ipsen, Les Ulis, France
[7] Ipsen, Basking Ridge, NJ USA
[8] Royal Free Hosp, London, England
[9] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
来源：
NEUROENDOCRINOLOGY | 2017年 / 105卷
关键词：
lanreotide; safety;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K17
引用
收藏
页码：206 / 206
页数：1
相关论文
共 35 条
  • [11] CLARINET FORTE: Characterization of Pharmacokinetics (PK), efficacy and safety in patients with progressive neuroendocrine tumors (NETs) treated with Lanreotide Autogel (LAN) 120 mg every 14 days (q14d)
    Dehez, M.
    Brendel, K.
    Sarr, C.
    Bjornsson, M.
    Thanh, Truong X. M.
    Pavel, M.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 133 - 133
  • [12] Open-Label Multicentre Single-Arm Phase 2 Trial of Lanreotide Autogel (LAN) in Combination with Temozolomide (TMZ) in Patients with Advanced Well/Moderately Differentiated Neuroendocrine Tumours (NETs) of Lung and Thymus: ATLANT
    Ferolla, P.
    Berruti, A.
    Fazio, N.
    Mazzanti, P.
    Houchard, A.
    NEUROENDOCRINOLOGY, 2017, 105 : 196 - 196
  • [13] Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results
    Pavel, M.
    Cwikla, J. B.
    Lombard-Bohas, C.
    Borbath, I
    Shah, T.
    Pape, U. F.
    Thanh, Truong X. M.
    Houchard, A.
    Ruszniewski, P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 143 - 143
  • [14] Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results
    Pavel, Marianne
    Cwikla, Jaroslaw B.
    Lombard-Bohas, Catherine
    Borbath, Ivan
    Shah, Tahir
    Pape, Ulrich F.
    Capdevila, Jaume
    Panzuto, Francesco
    Thanh, Xuan-Mai Truong
    Houchard, Aude
    Ruszniewski, Philippe
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 403 - 414
  • [15] Safety and Tolerability of Rufinamide in Children With Epilepsy: A Pooled Analysis of 7 Clinical Studies
    Wheless, James W.
    Conry, Joan
    Krauss, Gregory
    Mann, Allison
    LoPresti, Antonia
    Narurkar, Milind
    JOURNAL OF CHILD NEUROLOGY, 2009, 24 (12) : 1520 - 1525
  • [16] Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis
    Capdevila, Jaume
    Sevilla, Isabel
    Alonso, Vicente
    Anton Aparicio, Luis
    Jimenez Fonseca, Paula
    Grande, Enrique
    Jose Reina, Juan
    Luis Manzano, Jose
    Alonso Lajara, Juan Domingo
    Barriuso, Jorge
    Castellano, Daniel
    Medina, Javier
    Lopez, Carlos
    Segura, Angel
    Carrera, Sergio
    Crespo, Guillermo
    Fuster, Jose
    Munarriz, Javier
    Garcia Alfonso, Pilar
    BMC CANCER, 2015, 15
  • [17] Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis
    Jaume Capdevila
    Isabel Sevilla
    Vicente Alonso
    Luís Antón Aparicio
    Paula Jiménez Fonseca
    Enrique Grande
    Juan José Reina
    José Luís Manzano
    Juan Domingo Alonso Lájara
    Jorge Barriuso
    Daniel Castellano
    Javier Medina
    Carlos López
    Ángel Segura
    Sergio Carrera
    Guillermo Crespo
    José Fuster
    Javier Munarriz
    Pilar García Alfonso
    BMC Cancer, 15
  • [18] Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
    Timothy R. Smith
    Egilius L. H. Spierings
    Roger Cady
    Joe Hirman
    Barbara Schaeffler
    Vivienne Shen
    Bjørn Sperling
    Thomas Brevig
    Mette Krog Josiassen
    Elizabeth Brunner
    Loan Honeywell
    Lahar Mehta
    The Journal of Headache and Pain, 2021, 22
  • [19] Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
    Engel, Samuel S.
    Round, Elizabeth
    Golm, Gregory T.
    Kaufman, Keith D.
    Goldstein, Barry J.
    DIABETES THERAPY, 2013, 4 (01) : 119 - 145
  • [20] Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
    Samuel S. Engel
    Elizabeth Round
    Gregory T. Golm
    Keith D. Kaufman
    Barry J. Goldstein
    Diabetes Therapy, 2013, 4 : 119 - 145
1234